Global Ophthalmic Implants Market - Focused Insights 2025-2030

OPHTHALMIC IMPLANTS MARKET SIZE

The global ophthalmic implants market was valued at USD 5.28 billion in 2024 and is expected to reach USD 8.14 billion by 2030, growing at a CAGR of 7.48% during the forecast period. The market is rapidly evolving due to rising concerns about eye health, increasing prevalence of eye diseases, and advancements in ophthalmic implants. Growth is further driven by an aging population, higher rates of vision impairment, rising healthcare expenditure, and new product launches.

MARKET DEFINITION

Ophthalmic implants are medical devices used to improve vision, reconstruct eye structure, and treat moderate to severe eye conditions. Made from biocompatible materials like hydrogel and silicone, these implants can be placed intraocularly or extraocularly to restore vision, reshape the eye, or deliver drugs. Also known as eye or ocular implants, their use is rising with the growing prevalence of eye diseases.

OPHTHALMIC IMPLANTS MARKET NEWS

1. In 2024, Alimera Sciences was acquired by ANI Pharmaceuticals to expand its footprint into the ophthalmology sector. This transaction, which values at around $381 million. Alimera Sciences was offered 2 ophthalmic implants that treat posterior eye diseases.
2. In 2023, Carl Zeiss Meditech acquired DORC- Dutch Ophthalmic Research Centers to strengthen the company’s market position and leadership in vitreoretinal surgery and ophthalmic medical devices, including ophthalmic implants.
3. In 2024, Roche reintroduced the Susvimo – Eye Implant after 2 years of recall. This product is now approved by the US FDA and widely available across the global market. This product is a refillable eye implant that refills annually with a unique drug proposition to treat age-related macular degeneration (AMD).
4. In 2024, Johnson & Johnson Medtech- one of the global companies in eye health launched TECNIS PureSee (Intraocular Lens) to correct refractive presbyopia in Europe and the Middle East & Africa (EMEA).
5. In 2024, Occular Therapeutix, a biopharmaceutical company, announced that the first patients had been enrolled in the phase 3 SOL-R clinical studies evaluating repeat dosing of AXPAXLI implant for the treatment of a patient with wet AMD.

OPHTHALMIC IMPLANTS MARKET TRENDS & DRIVERS

Drug Delivery – a New Approach with Ocular Implants

Ocular implants are a key medical device segment in the ocular implants market, experiencing continuous advancements. With a rising global prevalence of eye diseases, there is an increasing demand for effective treatments. Drug delivery through ocular implants is an emerging trend, offering localized, long-term (up to two years) medication release. This has gained popularity as a treatment option. The demand for minimally invasive, convenient eye treatments is also driving interest in advanced corneal implants.

Increasing Attention Towards Advanced Ocular Devices

The growing acceptance of advanced ocular devices like artificial eyes and glaucoma implants is creating new opportunities for market players. Rising regulatory approvals are expected to boost sales for major companies in the coming years. Artificial corneal implants have gained significant recognition, especially among patients unable to tolerate donor corneas. According to the Cornea Research Foundation of America (2023), over 11 million people worldwide suffer from corneal blindness, but only 100,000 receive donor tissue annually, highlighting the increasing demand for artificial corneal implants.

OPHTHALMIC IMPLANTS MARKET SEGMENTATION INSIGHTS

1. By Product: In 2024, intraocular lenses (IOLs) accounted for over 77% of the global ophthalmic implants market share. As one of the most widely used implant types, IOLs correct various vision issues such as myopia, hyperopia, presbyopia, and astigmatism. These permanent implants reduce dependence on glasses and are used to treat several eye conditions, boosting their global popularity. Available in mono-focal, multifocal, EDoF, trifocal, Toric, and other forms, their adoption is further driven by advancements like blue-light blocking, Toric designs, and aberration-free technologies.
2. By Application: The glaucoma surgery segment is projected to grow at the fastest CAGR of 8.04% during the forecast period. Glaucoma, a major concern in both children and older adults, is driving the need for surgical interventions and ophthalmic implants. In these procedures, surgeons place a small tube on the eye's white surface to reduce fluid buildup and improve drug delivery, aiming to stabilize or lower intraocular pressure (IOP). With glaucoma affecting around 80 million people globally as of 2025—and being a leading cause of blindness, demand for effective surgical solutions continues to rise. Additionally, the increasing prevalence of myopia, a key glaucoma risk factor, is boosting segment growth.
3. By End-Users: The hospital segment holds the largest global ophthalmic implants market share. Hospitals are the primary revenue contributors, as ophthalmic implants are widely used in clinical surgeries and aesthetic procedures within these settings. The availability of advanced medical facilities and skilled eye surgeons drives the high volume of procedures performed in hospitals. Additionally, factors like accidental injuries, severe eye conditions, and the need for extended care contribute to increased hospital visits. According to BMJ Open Ophthalmology (2022), over 40% of cataract patients opt for hospital-based surgeries, supporting the segment’s continued growth.

GEOGRAPHICAL ANALYSIS

NORTH AMERICA OPHTHALMIC IMPLANTS MARKET

North America leads the global ophthalmic implants market, accounting for over 34% of the share. This growth is driven by high spending on eye care, a growing aging population, and the rising incidence of glaucoma, cataracts, and refractive errors. The U.S. is the primary contributor, with significant investment in eye care solutions and a high prevalence of diabetes-related eye conditions. According to the Population Reference Bureau (2024), the U.S. has over 53 million people aged 65 and above, and Canada has 8 million. More than 20% of this age group is affected by cataracts, fueling strong demand for ophthalmic treatments.

APAC OPHTHALMIC IMPLANTS MARKET

The Asia-Pacific (APAC) region is projected to grow at the highest rate, with a CAGR of 9.03% during the forecast period. India is expected to lead this growth, driven by a rising aging population, increasing eye disease prevalence, and higher healthcare spending. Although APAC accounts for 51% of the global population, about two-thirds of those with moderate to severe vision impairment are in South, East, and Central Asia. Notably, 90% of these cases are preventable or treatable with proper care, highlighting strong growth potential in the region.

OPHTHALMIC IMPLANTS MARKET VENDORS

The global ophthalmic implants market report covers data from 27 vendors. Leading companies like Alcon, ZEISS Group, Bausch + Lomb, and Johnson & Johnson hold the largest market shares. These vendors provide advanced ophthalmic implants that meet consumer needs and regulatory standards. They enhance product efficiency and strengthen their market presence through a strong brand reputation and global reach. Strategies such as product launches, mergers and acquisitions, and innovation with advanced technologies have intensified competition, helping these companies secure higher revenue shares.